Randomized Treatment Study of Inosiplex Versus Combined Inosiplex and Intraventricular Interferon-α in Subacute Sclerosing Panencephalitis (SSPE): International Multicenter Study

Abstract

The efficacy of oral inosiplex alone (group A) versus combined treatment of inosiplex (Isoprinosine) and intraventricular interferon-α2b (Intron A) (group B) in patients with subacute sclerosing panencephalitis (SSPE) was compared. One hundred and twenty-one patients who met the diagnostic criteria for subacute sclerosing panencephalitis and presented at stage 2 or less were randomized into group A or B. Data were analyzable on 67 patients who met the inclusion criteria and adhered to the protocol. The inosiplex dosage was 100 mg/kg/day to a maximum of 3 g/day, taken orally in three divided doses for 6 months. Interferon-α2b started with 100,000 U/m² and escalated to 1,000,000 U/m² over 5 inpatient days and then 1,000,000 U/m2 twice a week for 6 months. Neurologic status was rated by the Neurological Disability Index, Brief Assessment Examination, and stages. Kaplan-Meier survival rates were not statistically significant between group A and group B (log-rank test X² = .1374, P = .7109). In longitudinal morbidity analyses, regression results were fitted to three outcome measures: the Neurological Disability Index, the Brief Assessment Examination, and stage. Group medians of the estimated regression slopes were then compared using the Wilcoxon rank-sum test. There was no statistically significant difference between the two groups on any of these three measures. Morbidity comparisons of clinical classification of outcomes (improvement, stabilization, worsening after treatment stopped, deterioration) also showed no statistically signficant difference between groups. There were no statistically significant differences between the two treatment groups on any efficacy measure. However, the observed rates of satisfactory outcome (stabilization, improvement) of 34% in group A and 35% in group B were higher than the spontaneous remission rates of 5 to 10% reported in the literature, suggesting that treatment was superior to no treatment. (J Child Neurol 2003;18:819-827).

Get full access to this article

View all access options for this article.

References

Dyken PR : Subacute sclerosing panencephalitis: Current status. Neurology Clin 1985;3:179-196.

Haslam Rha , McQujillen MP , Clark DB : Amantadine therapy in SSPE. Neurology 1969 ;19:1080-1085.

Robertson WC Jr , Clark DB , Markesbery WR : Review of 39 cases of SSPE: Effect of amantadine on the natural course of the disease. Ann Neurol 1980;8:42-45.

Jones CE , Dyken PR , Huttenlocher PR , et al: Inosiplex therapy in SSPE, a multi-centre, non-randomized study in 98 patients. Lancet 1982;i:1034-1037.

Fukuyama Y. , Nihei I. , Matsumoto S. , et al, of the Inosiplex-SSPE Research Committee: Clinical effects of MDN-19 (inosiplex) on SSPE: A multi-institutional collective study. Brain Dev 1987:9:270-282.

Yalaz K. , Anlar B. , Oktem F. , et al: Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992;42:488-491.

Gascon GG , Yamani S. , Crowell J. , et al: Combined oral Isoprinosine-intraventricular alpha interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993;15:346-355.

Panitch HS : Treatment of subacute sclerosing panencephalitis with interferon, in Smith RA (ed): Interferon Treatment of Neurologic Disorders. New York, Marcel Dekker, 1988, 187-207.

Durant RH , Dyken PR , Swift A. : The influence of inosiplex treatment on the neurological disability of patients with SSPE. J Pediatr 1982;101:288-293.

10.

Nester M. : Use of a brief assessment exam in a study involving Isoprinosine and alpha interferon treatment of SSPE. J Child Neurol 1996;11:173-180.

11.

Oktem F. , Nester MJ , Anlar B. : Mental assessment in SSPE: Hacettepe Cognitive Short Assessment. J Child Neurol 1997; 11:398-402.

12.

Conrad AJ , Chiang EY , Andeen LE , Tourtellotte WW : Quantitation of intrathecal measles virus IgG antibody synthesis rate: SSPE and multiple sclerosis. J Neuroimmunol 1994 ;54:99-108.

13.

Anlar B. , Köse G. , Gürer Y. , et al: Changing epidemiological features of subacute sclerosing panencephalitis . Infection 2001;29:192-195.

14.

Hosoya M. , Shigeta S. , Mori S. , et al: High-dose intravenous ribvarin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001;45:943-945.

15.

Tomoda A. , Shiraishi S. , Hosoya M. , et al: Combined treatment with interferon-alpha and ribavarin for subacute sclerosing panencephalitis. Pediatr Neicrot 2001;24:54-59.

16.

Solomon T. , Hart CA , Vinjamuri S. , et al: Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavarin, and inosiplex. J Child Neurol 2002 ;17:703-705.

17.

Aydin OF , Senbil N. , Kuyucu N. , Gürer YK : Combined treatment with subcutaneous interferon-alpha, oral Isoprinosine, and lamivudine for subacute sclerosing panencephalitis. J Child Neurol 2003;18:104-108.

18.

Brismar J. , Gascon G. : Neuroimaging of the brain in 52 patients with subacute sclerosing panencephalitis . AJNR Am J Neuroradiol 1996 ;17:761-772.

19.

Anlar B. , Saatçi I. , Köse G. , Yalaz K. : MRI findings in subacute sclerosing panencephalitis. Neurology 1996;47:1278-1283.